Company Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
It develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
The company’s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.
The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy.
Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1997 |
| IPO Date | Apr 29, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 423 |
| CEO | Robert Blum |
Contact Details
Address: 350 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 624 3000 |
| Website | cytokinetics.com |
Stock Details
| Ticker Symbol | CYTK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001061983 |
| CUSIP Number | 23282W605 |
| ISIN Number | US23282W6057 |
| Employer ID | 94-3291317 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert I. Blum | Chief Executive Officer, President and Director |
| Robert C. Wong | Vice President and Chief Accounting Officer |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research and Development |
| Andrew M. Callos | Executive Vice President and Chief Commercial Officer |
| Dr. James A. Spudich Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Sung H. Lee | Executive Vice President and Chief Financial Officer |
| Jeff Lotz | Vice President of Sales and Operations |
| Matt Yang | Vice President of Corporate Finance and Financial Planning and Analysis |
| Steven M. Cook J.D. | Senior Vice President of Global Supply Chain Operations and Technical Operations |
| Kari K. Loeser J.D. | Vice President and Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | 8-K | Current Report |
| Dec 16, 2024 | 144 | Filing |
| Dec 11, 2024 | 144 | Filing |
| Dec 10, 2024 | 144 | Filing |
| Dec 2, 2024 | 144 | Filing |
| Nov 26, 2024 | 144 | Filing |
| Nov 25, 2024 | 144 | Filing |
| Nov 19, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |